RBF Capital’s Alto Neuroscience ANRO Stock Holding History

RBF Capital’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-27,359	Closed	-$59.1K	–	632
2025 Q1	$59.1K	Buy	+27,359	New	+$97.9K	﹤0.01%	562

Other funds holding ANRO

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

RBF Capital's ANRO Position: Q2 2025 in Review

RBF Capital sold out of Alto Neuroscience (ANRO) in Q2 2025, closing a stake of 27,359 shares — an estimated $59.1K sold.

RBF Capital first reported a position in ANRO in Q1 2025 and held it in 1 quarter. The position peaked at $59.1K in Q1 2025. 80 funds tracked by Wall St. Rank hold ANRO as of Q2 2025.

RBF Capital reported no remaining Alto Neuroscience position as of Q2 2025 after selling out during the quarter.
RBF Capital sold 27,359 Alto Neuroscience shares in Q2 2025, an estimated $59.1K.
RBF Capital first reported a position in Alto Neuroscience in Q1 2025 and held it in 1 quarter.
RBF Capital's Alto Neuroscience position peaked at $59.1K in Q1 2025.
80 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2025.

Based on RBF Capital's 13F filing for Q2 2025, filed 14 Aug 2025.